Treatment of Rhinitis Medicamentosa in Obstructive Sleep Apnea Patients on CPAP
Patients with obstructive sleep apnea using continuous positive airway pressure (CPAP) therapy can develop rhinitis medicamentosa as a direct consequence of CPAP-related nasal airway changes.
Clinical Scenario
CPAP prescribed for obstructive sleep apnea increases airflow through the nasal cavity. This sustained airflow can cause drying of the nasal mucous membranes, which in turn triggers overproduction of mucus and nasal congestion — the hallmark presentation of rhinitis medicamentosa in this setting.
Treatment Approach
Management focuses on optimising how the CPAP device is used and configured, combined with protective measures directed at the nasal mucosa. The structured protocol specifies the full sequence of interventions and their application — only a portion of the approach is outlined here.
References
CPAP prescribed for sleep apnea, can cause increased air flow through the nasal cavity, which, in turn, causes dry mucous membrane, overproduction of the mucus, and congestion.
Appropriate use of such machines should be ensured, including evaluation of pressure used, regular maintenance, and humidification of the air delivered.
Nasal gel is recommended to prevent drying of the mucous membranes of the nasal cavity.
View source ↗